Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus–associated oropharynx cancer early detection
- 10 September 2025
- journal article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (1) , 58-67
Abstract
Background: Early detection of HPV-associated oropharyngeal squamous cell carcinoma, the most common HPV cancer in the United States, could reduce disease-related morbidity and mortality, yet currently, there are no early detection tests. HPV circulating tumor DNA (ctDNA) is a sensitive and specific biomarker for HPV–associated oropharyngeal squamous cell carcinoma at diagnosis. It is unknown if ctDNA HPV is detectable prior to diagnosis, and thus its potential as an early detection test is also unknown. Methods: Plasma samples from the Mass General Brigham Biobank collected 1.3-10.8 years prior to diagnosis from HPV–associated oropharyngeal squamous cell carcinoma patients (n = 28) and age- and sex-matched controls (n = 28) were blinded and run on a newly developed and validated multifeature HPV whole genome sequencing liquid biopsy assay and a validated HPV antibody assay. Results: HPV ctDNA results were positive in 22 of 28 prediagnostic samples from HPV–associated oropharyngeal squamous cell carcinoma cases (sensitivity 79%) with a maximum lead time of 7.8 years. HPV ctDNA results were negative in all controls (0 of 28, 100% specificity). Diagnostic accuracy was highest within 4 years of cancer diagnosis and was higher than HPV Ab detection within the same timeframe (P = .004). Application of a machine-learning model trained and tested on an independent cohort of 306 cases and controls increased the sensitivity of detection to 27 of 28 cases (overall sensitivity 96%) and the maximum lead time to 10.3 years. Conclusions: HPV ctDNA can be detected in the blood years prior to diagnosis with HPV–associated oropharyngeal squamous cell carcinoma, with high specificity, in a case-control cohort of 56 participants. HPV ctDNA detection alone, or in combination with previously identified serological biomarkers, may be a feasible approach to early detection of HPV–associated oropharyngeal squamous cell carcinoma.Keywords
Funding Information
- NIH
- NIDCR (R03DE030550)
- NIDCR (K23 DE029811)
- NIDCR (R03 DE030550)
- NIDCR (R21 CA267152)
This publication has 29 references indexed in Scilit:
- Circulating Tumor HPV DNA for Surveillance of HPV-Positive Oropharyngeal Squamous Cell CarcinomaJAMA Oncology, 2023
- Detection of stage I HPV-driven oropharyngeal cancer in asymptomatic individuals in the Hamburg City Health Study using HPV16 E6 serology – A proof-of-concept studyeClinicalMedicine, 2022
- Association of Plasma Circulating Tumor HPV DNA With HPV-Related Oropharynx CancerJAMA Otolaryngology–Head & Neck Surgery, 2022
- Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV‐positive head and neck cancerInternational Journal of Cancer, 2022
- Projected Association of Human Papillomavirus Vaccination With Oropharynx Cancer Incidence in the US, 2020-2045JAMA Oncology, 2021
- Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trialOral Oncology, 2021
- Early Detection of Human Papillomavirus–Driven Oropharyngeal Cancer Using Serology From the Study of Prevention of Anal CancerJAMA Oncology, 2020
- Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16‐driven oropharyngeal squamous cell carcinomaInternational Journal of Cancer, 2017
- Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus–Related Oropharyngeal CarcinomaJAMA Oncology, 2015
- HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking statusOral Oncology, 2015